<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renin-angiotensin system inhibition in the treatment of hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renin-angiotensin system inhibition in the treatment of hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renin-angiotensin system inhibition in the treatment of hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johannes FE Mann, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karl F Hilgers, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inhibitors of the renin-angiotensin system (RAS), particularly angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), are commonly used in the treatment of hypertension. The role of the RAS in hypertension and the use of specific inhibitors of this system to treat hypertension will be reviewed here.</p><p>The use of RAS inhibitors in patients with kidney disease and diabetes is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p></p><p>The importance of local (ie, tissue) RAS activity in low-renin hypertension and the effects of angiotensin II on the heart are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Renin-angiotensin system'</a>.)</p><p></p><p>The safety of ACE inhibitors and ARBs in patients with coronavirus disease 2019 (COVID-19) is discussed in another topic:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Renin angiotensin system inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">ANGIOTENSIN-CONVERTING ENZYME INHIBITORS</span><span class="headingEndMark"> — </span>Since the introduction of <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a> in 1977 [<a href="#rid1">1</a>], angiotensin-converting enzyme (ACE) inhibitors have become widely used for the treatment of hypertension and three of its major complications: acute myocardial infarction, congestive heart failure, and chronic kidney disease. Fifty to 60 percent of White patients have a good response to monotherapy with ACE inhibitors, a response rate similar to other first-line antihypertensive drugs [<a href="#rid2">2</a>]. ACE inhibitors have the additional advantages of having a more favorable side effect profile than sympathetic blockers, beta blockers, and diuretics [<a href="#rid3">3</a>]. Various professional societies have recommended ACE inhibitors and angiotensin II receptor blockers (ARBs) as first- or second-line therapy in the treatment of hypertension [<a href="#rid4">4-7</a>]. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a> and  <a class="medical medical_review" href="/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a> and  <a class="medical medical_review" href="/d/html/3838.html" rel="external">"Treatment of hypertension in patients with heart failure"</a> and  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Specific indications for use</span><span class="headingEndMark"> — </span>There are a number of settings in which ACE inhibitors are the antihypertensive drugs of choice because of possible benefits in addition to lowering the blood pressure. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure with reduced ejection fraction (HFrEF) [<a href="#rid8">8</a>] (see  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Primary components of therapy'</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proteinuric chronic kidney disease, both diabetic and nondiabetic [<a href="#rid9">9</a>] (see  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/3089.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After a myocardial infarction in most patients, particularly those with heart failure or reduced systolic function [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Antihypertensive response</span><span class="headingEndMark"> — </span>The decline in blood pressure seen with ACE inhibitors appears to be primarily due to decreased formation of angiotensin II, but decreased degradation of kinins could contribute by both direct vasodilation and increasing the production of vasodilator prostaglandins [<a href="#rid11">11</a>].</p><p>Black patients may be less sensitive than White patients to ACE inhibitors as monotherapy for hypertension [<a href="#rid12">12</a>]. However, the addition of even a low dose of a thiazide diuretic to an ACE inhibitor leads to a fall in blood pressure that is comparable with that seen in White patients [<a href="#rid13">13</a>].</p><p>The utility of ACE inhibitors with diuretics is not limited to Black patients, since these drugs have a synergistic effect, attaining goal blood pressure in up to 85 percent of patients with mild hypertension [<a href="#rid13">13</a>]. The antihypertensive response to diuretics is often limited by the hypovolemia-induced increase in renin release and subsequent angiotensin II production [<a href="#rid14">14</a>]; this effect is prevented by converting enzyme inhibition, leading to a more prominent reduction in blood pressure (see  <a class="medical medical_review" href="/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension"</a>). For similar reasons, dietary sodium restriction can also enhance the response to an ACE inhibitor [<a href="#rid15">15</a>].</p><p>ACE inhibitors minimize some of the metabolic changes induced by diuretic therapy. Hypokalemia, for example, is less prominent because the reduction in angiotensin II formation induced by the ACE inhibitor leads to decreased secretion of aldosterone. ACE inhibitors also do not induce glucose intolerance, hyperlipidemia, or hyperuricemia; may increase insulin sensitivity; and may minimize or prevent diuretic-induced elevations in serum glucose, cholesterol and uric acid levels [<a href="#rid16">16</a>].</p><p>Apart from diuretics, calcium channel blockers can be used effectively with ACE inhibitors and, as shown in the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, may have clinical advantages over diuretics when achieved blood pressure is similar. Combination of an ACE inhibitor with a beta blocker may be less useful because of inferior antihypertensive activity compared with other ACE inhibitor combinations [<a href="#rid17">17</a>]. This relative lack of efficacy may be due in part to similar mechanisms of action, as angiotensin II formation and renin secretion are respectively reduced. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Dose</span><span class="headingEndMark"> — </span>As with other antihypertensive agents, proper dose can minimize the incidence of side effects  (<a class="graphic graphic_table graphicRef64770" href="/d/graphic/64770.html" rel="external">table 1</a>). To minimize the risk of first-dose hypotension due to an abrupt decline in angiotensin II levels, the patient should not be volume depleted. The initial dose can be reduced by one-half in older adult patients or those with heart failure who are at higher risk for hypotension. Side effects other than those related to hypotension can occur with ACE inhibitors, the most common being cough [<a href="#rid18">18</a>], less commonly hyperkalemia, and rarely angioedema [<a href="#rid19">19</a>]. ACE inhibitors are <strong>contraindicated</strong> during pregnancy [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p>The duration of action varies with different ACE inhibitors. Some ACE inhibitors can be given once daily (eg, <a class="drug drug_general" data-topicid="10171" href="/d/drug information/10171.html" rel="external">trandolapril</a>, <a class="drug drug_general" data-topicid="9565" href="/d/drug information/9565.html" rel="external">lisinopril</a>, and <a class="drug drug_general" data-topicid="9081" href="/d/drug information/9081.html" rel="external">benazepril</a>). The use of longer-acting agents once daily should improve patient compliance, reduce costs, maintain smoother control, and ensure that the abrupt rise in pressure upon awakening in the early morning is blunted, hopefully thereby reducing the incidence of serious cardiovascular events at this time.</p><p>After the initiation of therapy, the patient should be reexamined in a few weeks to allow the full antihypertensive effect to occur. If there is no or little fall in blood pressure with an adequate dose, the drug can be stopped and different class of drug started, a concept called "sequential monotherapy." Alternatively, another drug may be added, such as a calcium channel blocker. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>If the patient's blood pressure is reduced by the ACE inhibitor but the goal pressure is not achieved, the dose can be gradually increased to the maximum levels noted in the table  (<a class="graphic graphic_table graphicRef64770" href="/d/graphic/64770.html" rel="external">table 1</a>). However, the addition of a second drug from a different class will provide much greater antihypertensive effect [<a href="#rid21">21</a>].</p><p>In patients with extensive atherosclerosis or kidney function impairment who are more likely to have renovascular stenoses, a repeat plasma creatinine concentration should be obtained within one to two weeks of ACE inhibitor or ARB initiation to ensure that kidney perfusion has been maintained. However, a modest and nonprogressive increase in the plasma creatinine in such patients should <strong>not</strong> prompt discontinuation of therapy. (See  <a class="medical medical_review" href="/d/html/3873.html" rel="external">"Renal effects of ACE inhibitors in hypertension", section on 'Renovascular hypertension'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">ANGIOTENSIN II RECEPTOR BLOCKERS</span><span class="headingEndMark"> — </span>Angiotensin II receptor blockers (ARBs) interfere with the RAS by impairing the binding of angiotensin II to the AT1 receptor on the cell membrane, thereby inhibiting the action of angiotensin II [<a href="#rid22">22</a>]. Blockade of the action of angiotensin II leads to elevations in plasma levels of renin, angiotensin I, and angiotensin II. However, this build-up of precursors does not overwhelm the receptor blockade, as evidenced by a persistent fall in both blood pressure and plasma aldosterone levels [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Differences between ACE inhibitors and ARBs</span><span class="headingEndMark"> — </span>There are substantial pharmacologic differences in the actions of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), but few clinical differences have been documented. At least three factors may contribute to the pharmacologic differences  (<a class="graphic graphic_figure graphicRef55726" href="/d/graphic/55726.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>ACE is a <strong>kininase</strong>. Thus, inhibiting this enzyme, which normally degrades bradykinin, with an ACE inhibitor leads to increased kinin levels, an effect not seen with an ARB. This is likely responsible for the cough that may be seen with ACE inhibitors (but not with ARBs), although high bradykinin levels may also provide additional vasodilation and other benefits not observed with ARBs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By decreasing angiotensin II production, ACE inhibitors reduce the effect of both AT1 and AT2 receptors; only the former are inhibited by the ARBs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the heart, kidney, and perhaps the blood vessels, the production of angiotensin II may be catalyzed by enzymes other than ACE, such as chymase [<a href="#rid24">24</a>]. The effect of the angiotensin II produced by this reaction can be inhibited by the ARBs but not by ACE inhibitors. However, the role of these non-ACE enzymes for the generation of angiotensin II <strong>in vivo</strong>, if any, is uncertain.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Efficacy and dose</span><span class="headingEndMark"> — </span>The ARBs have an effect similar to that seen with monotherapy with other antihypertensive drugs  (<a class="graphic graphic_table graphicRef64770" href="/d/graphic/64770.html" rel="external">table 1</a>) [<a href="#rid25">25</a>]. However, several studies have shown that <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a>, when given once daily, does not control blood pressure to the same magnitude as other ARBs (<a class="drug drug_general" data-topicid="8640" href="/d/drug information/8640.html" rel="external">irbesartan</a>, <a class="drug drug_general" data-topicid="10275" href="/d/drug information/10275.html" rel="external">telmisartan</a>, <a class="drug drug_general" data-topicid="8670" href="/d/drug information/8670.html" rel="external">candesartan</a>, and <a class="drug drug_general" data-topicid="10036" href="/d/drug information/10036.html" rel="external">valsartan</a>) [<a href="#rid26">26-29</a>]. On the other hand, losartan produces a slight fall in plasma uric acid that does not occur with the other ARBs, an effect that is due to enhanced uric acid excretion [<a href="#rid30">30</a>]. This appears to be mediated at least in part by direct inhibition of the proximal urate-anion exchanger that is responsible for urate reabsorption [<a href="#rid31">31</a>].</p><p>The antihypertensive efficacy of ARBs appears to be roughly equivalent to that of the ACE inhibitors. A meta-analysis of 61 studies that directly compared angiotensin II receptor blockers and ACE inhibitors reported no difference in the antihypertensive effects of these agents [<a href="#rid25">25</a>].</p><p>In addition, the effects of ARBs and ACE inhibitors on cardiovascular events appear similar. The Ongoing <a class="drug drug_general" data-topicid="10275" href="/d/drug information/10275.html" rel="external">Telmisartan</a> Alone and in Combination with <a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">Ramipril</a> Global Endpoint Trial (ONTARGET) compared telmisartan (80 mg/day), ramipril (10 mg/day), and combination therapy (80 + 10 mg/day) with both agents in 25,620 patients with vascular disease or diabetes [<a href="#rid32">32</a>]. The primary outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. Achieved mean blood pressure was lower in patients who received telmisartan compared with ramipril (by 0.9/0.6 mmHg) and in patients who received both agents compared with ramipril (2.4/1.4 mmHg). The cardiovascular outcomes were similar in all three groups, while cough was more common with ramipril, and both hyperkalemia and acute kidney injury were more common with combined therapy. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p>In addition, a meta-analysis of nine trials and 11,007 patients that directly compared ACE inhibitors with ARBs in hypertensive patients found similar rates of all-cause mortality and cardiovascular mortality [<a href="#rid33">33</a>]. By contrast, drug withdrawal due to adverse events was significantly more frequent with ACE inhibitors (one additional withdrawal from therapy for every 55 patients treated with ACE inhibitors over four years), mostly due to dry cough. Thus, ARBs are a reasonable alternative to ACE inhibitor therapy in hypertensive patients.</p><p>As with other agents that inhibit the RAS, the efficacy of ARBs is enhanced by concomitant administration of low doses of a diuretic [<a href="#rid34">34</a>] and by a reduction in dietary sodium intake. As with ACE inhibitors, ARBs appear to minimize the hypokalemia and hyperuricemia induced by diuretic therapy [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H11"><span class="h1">SIDE EFFECTS</span><span class="headingEndMark"> — </span>Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are generally well tolerated. Cough and angioedema are less common with ARBs [<a href="#rid32">32</a>]. Both ACE inhibitors and ARBs are contraindicated in pregnancy. These issues, as well as other side effects from these medications, are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">ACE inhibitors plus ARBs</span><span class="headingEndMark"> — </span>A separate issue is the side effects associated with combined angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor blocker (ARB) therapy compared with either drug alone. The Ongoing <a class="drug drug_general" data-topicid="10275" href="/d/drug information/10275.html" rel="external">Telmisartan</a> Alone and in Combination with <a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">Ramipril</a> Global Endpoint Trial (ONTARGET) cited above of high-risk patients [<a href="#rid32">32,35</a>] found a significant increase in adverse effects (including a possible increase in mortality) with combined therapy compared with an ACE inhibitor alone. As a result, combined therapy is <strong>not</strong> recommended for the treatment of hypertension.</p><p>The data supporting adverse effects and the possible role of combined therapy to slow progression in patients with proteinuric chronic kidney disease are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">DIRECT RENIN INHIBITORS</span><span class="headingEndMark"> — </span>The first effective oral direct renin inhibitor, <a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">aliskiren</a>, became available in the United States in March 2007. However, it is rarely used and is no longer available in some countries.</p><p><a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">Aliskiren</a> lowers blood pressure to a degree comparable with most other agents [<a href="#rid36">36</a>]. A number of studies have evaluated the blood pressure-lowering effect of aliskiren in combination with other antihypertensive drugs [<a href="#rid36">36-39</a>]. In one report, the combination of maximum doses of aliskiren and <a class="drug drug_general" data-topicid="10036" href="/d/drug information/10036.html" rel="external">valsartan</a> decreased blood pressure more than maximum doses of either agent alone but not more than would be expected with dual therapy using drugs from different classes [<a href="#rid40">40</a>]. Aliskiren, as with other inhibitors of the RAS, should <strong>not</strong> be used in pregnancy.</p><p>In the <a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">Aliskiren</a> in the Evaluation of Proteinuria in Diabetes (AVOID) trial, aliskiren plus <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> was associated with a significant 20 percent greater reduction in proteinuria compared with losartan alone in patients with type 2 diabetes and nephropathy, in the absence of a significantly greater effect on blood pressure [<a href="#rid41">41</a>]. However, this effect on proteinuria did <strong>not</strong> translate into a clinical benefit. In the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE), 8600 patients with type 2 diabetes and kidney disease already taking either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) were randomly assigned to additional therapy with aliskiren or placebo [<a href="#rid42">42</a>]. The ALTITUDE trial was stopped early because of futility (no benefit on the primary cardiovascular and kidney outcomes) and because aliskiren therapy produced a nonsignificantly higher rate of adverse events (ie, nonfatal stroke, hypotension). The ALTITUDE trial is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p>The effect of <a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">aliskiren</a> on progression of atherosclerotic coronary artery disease in patients with controlled hypertension was examined in the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) [<a href="#rid43">43</a>]. In this trial, 613 patients with a systolic blood pressure between 125 and 139 mmHg (most of whom were treated with antihypertensive medications) and two other cardiovascular risk factors were randomly assigned to aliskiren (300 mg/day) or placebo. After 18 months, the atherosclerotic burden and progression of atherosclerosis (measured by coronary intravascular ultrasound) was similar between the groups. In a secondary analysis based upon a small number of events, aliskiren appeared to reduce the rate of cardiovascular events. However, this analysis excluded diabetic patients who were treated with angiotensin inhibitors (approximately 15 percent of the study population), as such patients were removed from the study after publication of the ALTITUDE trial [<a href="#rid44">44</a>]. In addition, adverse events were more common with aliskiren.</p><p>An increased risk of hyperkalemia when <a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">aliskiren</a> is combined with ACE inhibitors or ARBs has been described in the ALTITUDE trial and in other studies [<a href="#rid42">42,45</a>]. Thus, aliskiren should not be combined with ACE inhibitors or ARBs [<a href="#rid46">46</a>]; it may be used as a third-line agent if patients do not tolerate ACE inhibitors or ARBs.</p><p class="headingAnchor" id="H983513"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibitors of the renin-angiotensin system (RAS), including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and direct renin inhibitors are commonly used in the treatment of hypertension. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are a number of settings in which ACE inhibitors are the antihypertensive drugs of choice because of possible benefits in addition to lowering the blood pressure (see <a class="local">'Specific indications for use'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure with reduced ejection fraction (HFrEF)</p><p class="bulletIndent2"><span class="glyph">•</span>Proteinuric chronic kidney disease, both diabetic and nondiabetic</p><p class="bulletIndent2"><span class="glyph">•</span>After a myocardial infarction in most patients, particularly those with heart failure or reduced systolic function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proper dose of ACE inhibitors can minimize the incidence of side effects  (<a class="graphic graphic_table graphicRef64770" href="/d/graphic/64770.html" rel="external">table 1</a>). The duration of action varies with different ACE inhibitors. Some ACE inhibitors can be given once daily (eg, <a class="drug drug_general" data-topicid="10171" href="/d/drug information/10171.html" rel="external">trandolapril</a>, <a class="drug drug_general" data-topicid="9565" href="/d/drug information/9565.html" rel="external">lisinopril</a>, and <a class="drug drug_general" data-topicid="9081" href="/d/drug information/9081.html" rel="external">benazepril</a>). (See <a class="local">'Dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are pharmacologic differences in the actions of ACE inhibitors and ARBs. Except for the cough associated with ACE inhibitors, these pharmacologic differences are not associated with clinically meaningful differences in therapeutic effects. At least three factors may contribute to the pharmacologic differences  (<a class="graphic graphic_figure graphicRef55726" href="/d/graphic/55726.html" rel="external">figure 1</a>) (see <a class="local">'Differences between ACE inhibitors and ARBs'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACE is a <strong>kininase</strong>. Thus, inhibiting this enzyme, which normally degrades bradykinin, with an ACE inhibitor leads to increased kinin levels, an effect not seen with an ARB. This is likely responsible for the cough that may be seen with ACE inhibitors (but not with ARBs), although high bradykinin levels may also provide additional vasodilation and other benefits not observed with ARBs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By decreasing angiotensin II production, ACE inhibitors reduce the effect of both AT1 and AT2 receptors; only the former are inhibited by the ARBs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the heart, kidney, and perhaps the blood vessels, the production of angiotensin II may be catalyzed by enzymes other than ACE, such as chymase. The effect of the angiotensin II produced by this reaction can be inhibited by the ARBs but not by ACE inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ARBs have an effect similar to that seen with monotherapy with other antihypertensive drugs, including ACE inhibitors  (<a class="graphic graphic_table graphicRef64770" href="/d/graphic/64770.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The antihypertensive effect of both ACE inhibitors and ARBs is enhanced by concomitant administration of low doses of a diuretic and by a reduction in dietary sodium intake. Both drugs also appear to minimize the hypokalemia and hyperuricemia induced by diuretic therapy. (See <a class="local">'Dose'</a> above and <a class="local">'Efficacy and dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both ACE inhibitors and ARBs are generally well tolerated. Side effects other than those related to hypotension can occur with both drugs, including hyperkalemia and rarely angioedema, as well as acute kidney injury in patients with low effective arterial blood volume (eg, diarrhea, vomiting, and heart failure). Cough is a common side effect of ACE inhibitors. ACE inhibitors and ARBs are <strong>contraindicated</strong> during pregnancy. (See <a class="local">'Side effects'</a> above and  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined therapy with both an ACE inhibitor and ARB is <strong>not</strong> recommended for the treatment of hypertension. (See <a class="local">'ACE inhibitors plus ARBs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first effective oral direct renin inhibitor, <a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">aliskiren</a>, lowers blood pressure to a degree comparable with most other agents. In combination with an ACE inhibitor or ARB, aliskiren increases the risk of adverse effects and does not lower the risk of cardiovascular event. Thus, aliskiren should <strong>not</strong> be combined with ACE inhibitors or ARBs. (See <a class="local">'Direct renin inhibitors'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196:441.</a></li><li><a class="nounderline abstract_t">Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713.</a></li><li><a class="nounderline abstract_t">Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314:1657.</a></li><li><a class="nounderline abstract_t">Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.</a></li><li><a class="nounderline abstract_t">Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751.</a></li><li><a class="nounderline abstract_t">Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.</a></li><li><a class="nounderline abstract_t">Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.</a></li><li><a class="nounderline abstract_t">Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25.</a></li><li><a class="nounderline abstract_t">Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.</a></li><li><a class="nounderline abstract_t">Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150:1175.</a></li><li><a class="nounderline abstract_t">Vaughan ED Jr, Carey RM, Peach MJ, et al. The renin response to diuretic therapyl A limitation of antihypertensive potential. Circ Res 1978; 42:376.</a></li><li><a class="nounderline abstract_t">Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.</a></li><li><a class="nounderline abstract_t">Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868.</a></li><li><a class="nounderline abstract_t">Pickering TG. The use of angiotensin converting enzyme inhibitors in combination with other antihypertensive agents. Am J Hypertens 1991; 4:73S.</a></li><li><a class="nounderline abstract_t">Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010; 123:1016.</a></li><li><a class="nounderline abstract_t">Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29:2273.</a></li><li><a class="nounderline abstract_t">Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.</a></li><li><a class="nounderline abstract_t">Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290.</a></li><li><a class="nounderline abstract_t">Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637.</a></li><li><a class="nounderline abstract_t">Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7:1041.</a></li><li><a class="nounderline abstract_t">Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14:1738.</a></li><li><a class="nounderline abstract_t">Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148:16.</a></li><li><a class="nounderline abstract_t">Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11:445.</a></li><li><a class="nounderline abstract_t">Mallion J, Siche J, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657.</a></li><li><a class="nounderline abstract_t">Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7:53.</a></li><li><a class="nounderline abstract_t">Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12:414.</a></li><li><a class="nounderline abstract_t">Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13:1343.</a></li><li><a class="nounderline abstract_t">Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.</a></li><li><a class="nounderline abstract_t">ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.</a></li><li><a class="nounderline abstract_t">Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2014; :CD009096.</a></li><li><a class="nounderline abstract_t">Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26:112.</a></li><li><a class="nounderline abstract_t">Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.</a></li><li><a class="nounderline abstract_t">Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49:1157.</a></li><li><a class="nounderline abstract_t">Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11.</a></li><li><a class="nounderline abstract_t">Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25:217.</a></li><li><a class="nounderline abstract_t">Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008; 121:265.</a></li><li><a class="nounderline abstract_t">Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221.</a></li><li><a class="nounderline abstract_t">Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433.</a></li><li><a class="nounderline abstract_t">Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204.</a></li><li><a class="nounderline abstract_t">Nicholls SJ, Bakris GL, Kastelein JJ, et al. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 2013; 310:1135.</a></li><li><a class="nounderline abstract_t">Tardif JC, Grégoire J. Renin-angiotensin system inhibition and secondary cardiovascular prevention. JAMA 2013; 310:1130.</a></li><li><a class="nounderline abstract_t">Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012; 344:e42.</a></li><li><a class="nounderline abstract_t">Rajagopalan S, Bakris GL, Abraham WT, et al. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension 2013; 62:444.</a></li></ol></div><div id="topicVersionRevision">Topic 3815 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/191908" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336373" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3520318" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The effects of antihypertensive therapy on the quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868454" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of hypertension: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762635" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10376615" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Optimisation of antihypertensive treatment by crossover rotation of four major classes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2057034" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114537" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386652" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7784479" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8446138" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191634" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/624143" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The renin response to diuretic therapyl A limitation of antihypertensive potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791491" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671740" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009154" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The use of angiotensin converting enzyme inhibitors in combination with other antihypertensive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21035591" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970934" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010128" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19272490" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696996" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Angiotensin II receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702796" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12819233" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984484" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607383" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516734" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551878" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232502" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8984133" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12024214" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Molecular identification of a renal urate anion exchanger that regulates blood urate levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378520" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Telmisartan, ramipril, or both in patients at high risk for vascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148386" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7607713" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18707986" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17367658" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17198906" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143194" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374681" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17658393" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525041" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Aliskiren combined with losartan in type 2 diabetes and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121378" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cardiorenal end points in a trial of aliskiren for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999933" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999917" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Renin-angiotensin system inhibition and secondary cardiovascular prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232539" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23876474" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
